GlassScriptPhysician profile
Milcah Larks
NPI 1922010081
$2,417.05
in general payments reported to CMS, 2019-2025
37 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $211 · 2021: $266 · 2022: $521 · 2023: $67.11 · 2024: $414 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $224.77 | 2019-2025 | Rybrevant |
| Pfizer INC. | $212.96 | 2019-2025 | |
| Seagen INC. | $206.25 | 2019-2023 | Padcev |
| Genentech USA, INC. | $150.86 | 2019-2025 | Itovebi, Lunsumio, Columvi |
| Exelixis INC. | $140.27 | 2019-2022 | |
| Celgene Corporation | $123.81 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $90.96 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $90.57 | 2019-2024 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $88.77 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $86.04 | 2019-2025 | Keytruda, Welireg |
| Array Biopharma INC | $83.81 | 2019-2025 | Braftovi, Tukysa, Mektovi |
| Daiichi Sankyo INC. | $83.21 | 2022-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $81.14 | 2020-2024 | Zejula, Jemperli, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $76.46 | 2019-2024 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $57.30 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $56.09 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $54.78 | 2024-2025 | Brukinsa, Tevimbra |
| Verastem, INC. | $54.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.64 | 2023-2025 | Lynozyfic, Libtayo |
| Astellas Pharma US INC | $40.24 | 2019 | |
| Genentech, INC. | $32.48 | 2019 | |
| Dendreon Pharmaceuticals LLC | $32.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $29.17 | 2022 | |
| Beone Medicines USA, INC. | $28.55 | 2025 | Tevimbra |
| Mirati Therapeutics, INC. | $25.82 | 2024 | Krazati |
| Incyte Corporation | $25.38 | 2022 | |
| Amgen INC. | $24.99 | 2020 | |
| Aveo Pharmaceuticals, INC. | $23.79 | 2022 | |
| Agios Pharmaceuticals, INC. | $21.88 | 2019 | |
| G1 Therapeutics, INC. | $20.94 | 2022 | |
| Emd Serono, INC. | $16.62 | 2025 | |
| Abbvie INC. | $16.40 | 2024 | |
| Servier Pharmaceuticals LLC | $16.32 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.51 | 2019 | |
| Advanced Accelerator Applications | $12.97 | 2020 | |
| Mission Pharmacal Company | $11.28 | 2019 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milcah Larks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.